Serum deoxythymidine kinase in small cell carcinoma of the lung: Relation to clinical features, prognosis, and other biochemical markers
Open Access
- 1 July 1986
- Vol. 58 (1) , 111-118
- https://doi.org/10.1002/1097-0142(19860701)58:1<111::aid-cncr2820580120>3.0.co;2-k
Abstract
Thymidine kinase (s-TK), lactate dehydrogenase (LDH), and carcinoembryonic antigen (CEA) were determined in pretreatment serum from 125 patients with small cell carcinoma of the lung. The distribution of marker levels into three ranges, when including all patients were as follows: s-TK Cancer 58:111–118, 1986.This publication has 23 references indexed in Scilit:
- Serum deoxythymidine kinase gives prognostic information in chronic lymphocytic leukemiaCancer, 1984
- Serum thymidine kinase in acute leukaemiaBritish Journal of Cancer, 1984
- Application of an in vitro assay for serum thymidine kinase: Results on viral disease and malignancies in humansInternational Journal of Cancer, 1984
- The use of serum deoxythymidine kinase as a prognostic marker, and in the monitoring of patients with non-Hodgkin's lymphomaBritish Journal of Cancer, 1983
- Prognostic relevance of thymidine kinase isozymes in adult non- Hodgkin's lymphomaBlood, 1981
- Viral-associated and induced enzymesPharmacology & Therapeutics, 1979
- Design and analysis of randomized clinical trials requiring prolonged observation of each patient. II. Analysis and examplesBritish Journal of Cancer, 1977
- Cell kinetic studies in patients with small cell carcinoma of the lungCancer, 1974
- Alkylating agents in bronchogenic carcinomaThe American Journal of Medicine, 1969
- The use of the nitrogen mustards in the palliative treatment of carcinoma.With particular reference to bronchogenic carcinomaCancer, 1948